All rights reserved.
Watch past educational presentations and see live events in real timeReference our medication guides for helpful informationExplore available award and grant opportunities for fellows-in-training.The best care starts with the best information.
Individual plans may vary
2002
/viewarticle/935260
See videos to help answer your questions.The ACR is accepting applications for mini curriculums, which are educational activities or curriculums to enhance the ACR Core Curriculum Outline.Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
No structural abnormalities were observed on animal reproduction studies, when pegloticase administered by subcutaneous injection to pregnant rats and rabbits during period of organogenesis at doses up to 50 and 75 times, respectively, the maximum recommended human dose (MRHD); decreases in mean fetal and pup body weights were observed at approximately 50 and 75 times MRHD, respectively encoded search term (pegloticase (Krystexxa)) and pegloticase (Krystexxa) Urate-Lowering Therapy for the Prevention and Treatment of Gout FlareNew FDA Watch List Covers 27 Drugs and Drug ClassesResearch Examines Links Between 'Long COVID' and ME/CFSCough-Induced Rib Fractures in a Frequent Tea DrinkerSome Rheumatic Diseases Tied to Higher Risk of Severe COVID-19Worldwide, Gout Cases and Years of Disability RisingShare cases and questions with Physicians on Medscape consult. Administration of a single dose of pegloticase results in rapid and sustained reduction of plasma urate levels in patients with gout (7, 8).
Some patients receiving pegloticase develop anti-drug antibodies, which leads to both loss of pegloticase efficacy and an increased risk for infusion reactions. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. This website also contains material copyrighted by 3rd parties.
colcrys-mitigare-colchicine-342812
2010
Your list will be saved and can be edited at any time.The above information is provided for general
Pegloticase at similar to and higher than the maximum recommended human dose (MRHD) on a plasma AUC basis [at intravenous (IV) doses of ≥ 0.4 mg/kg in dogs] caused cytoplasmic vacuoles in multiple organs, and edema and histiocyte infiltration in the aortic outflow tract in dogs.